CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Inyx, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Inyx, Inc.
825 Third Avenue, 40Th Floor,
Phone: (212) 838-1111p:212 838-1111 NEW YORK, NY  10022-7592  United States Ticker: IYXIIYXI
Business Summary
Inyx, Inc. is a provider of specialty pharmaceutical products and technologies. Its operations are focused on the development of both prescriptions, over the counter pharmaceutical products, and specialty consulting services. Also, the Company utilizes niche drug delivery capabilities to develop its own products. The product and service categories of the Company include Metered Dose Inhalers (MDIs) (CFC & HFA), Dry Powder Inhalers (DPIs), Metered Dose Pump Sprays (nasal and oral), Hydrocarbon Foam Aerosols, Saline Aerosols, Sterile Solutions/Injectables, Solid Dose, Formulation Services, Analytical Development Validation, Stability Services, Regulatory Support and Integrated Project Management.
(Source: PRESS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200612/31/2005YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer JackKachkar 45
President StevenHandley 49 7/2/2007 7/2/2007
Executive Vice President, Chief Scientific Officer ColinHunter 55 7/2/2007 7/2/2007
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Inyx USA Ltd. Parque Industrial Cotto Norte Carr. 604 Manatal PR United States

Business Names
Business Name
Ashton Pharmaceuticals Ltd.
Exaeris Inc.
Inyx Canada Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 572 (As of 12/31/2005)
Outstanding Shares: 53,106,650 (As of 11/30/2006)
Shareholders: 235
Stock Exchange: OTC
Federal Tax Id: 752870720
Fax Number: (212) 838-0060


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023